Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery

Research output: Contribution to journalArticle

Abstract

Early post-operative aspirin improves survival in patients undergoing coronary artery bypass graft (CABG). However, most patients do not benefit of aspirin after CABG, still remaining at risk of thrombotic events due to insufficient platelet inhibition, specifically via the thromboxane (TX) pathway. We evaluated the effect of two aspirin doses (100 or 325 mg daily, enteric coated formulations) on platelet function and TX biosynthesis in patients after CABG and assessed whether the incidence of residual platelet reactivity could be reduced by the higher dose. Fifty-six patients undergoing CABG were randomly assigned to 100 or 325 mg aspirin daily for five days in a prospective single-centre study. Treatment effect was assessed by measuring either platelet function (light-transmission aggregometry and point-of-care PFA-100® ) or TX biosynthesis in collagen-stimulated platelets, serum, urine, and in lipopolysaccharide (LPS)-cultured whole blood (WB). An insufficient TX inhibition was observed with 100 mg aspirin but not with the higher dose. The different effect of the two doses was, however, highlighted by either TX (platelet- or serum-derived) or by PFA-100® but not by the other assays. In conclusion, early after CABG, the incidence of residual platelet activity was lower in patients who received 325 mg aspirin. Moreover, evidence was provided that different methods yield different results in the detection of aspirin resistance, rendering them not interchangeable.

Original languageEnglish
Pages (from-to)516-524
Number of pages9
JournalThrombosis and Haemostasis
Volume103
Issue number3
DOIs
Publication statusPublished - Mar 2010

Fingerprint

Thromboxanes
Aspirin
Blood Platelets
Coronary Artery Bypass
Transplants
Point-of-Care Systems
Incidence
Serum
Lipopolysaccharides
Collagen
Urine
Light
Survival

Keywords

  • Aspirin
  • Coronary surgery
  • Platelet aggregation
  • Platelet pharmacology
  • Thromboxane

ASJC Scopus subject areas

  • Hematology

Cite this

@article{83000a77088744c9aeb08dfe633800af,
title = "Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery",
abstract = "Early post-operative aspirin improves survival in patients undergoing coronary artery bypass graft (CABG). However, most patients do not benefit of aspirin after CABG, still remaining at risk of thrombotic events due to insufficient platelet inhibition, specifically via the thromboxane (TX) pathway. We evaluated the effect of two aspirin doses (100 or 325 mg daily, enteric coated formulations) on platelet function and TX biosynthesis in patients after CABG and assessed whether the incidence of residual platelet reactivity could be reduced by the higher dose. Fifty-six patients undergoing CABG were randomly assigned to 100 or 325 mg aspirin daily for five days in a prospective single-centre study. Treatment effect was assessed by measuring either platelet function (light-transmission aggregometry and point-of-care PFA-100{\circledR} ) or TX biosynthesis in collagen-stimulated platelets, serum, urine, and in lipopolysaccharide (LPS)-cultured whole blood (WB). An insufficient TX inhibition was observed with 100 mg aspirin but not with the higher dose. The different effect of the two doses was, however, highlighted by either TX (platelet- or serum-derived) or by PFA-100{\circledR} but not by the other assays. In conclusion, early after CABG, the incidence of residual platelet activity was lower in patients who received 325 mg aspirin. Moreover, evidence was provided that different methods yield different results in the detection of aspirin resistance, rendering them not interchangeable.",
keywords = "Aspirin, Coronary surgery, Platelet aggregation, Platelet pharmacology, Thromboxane",
author = "Marta Brambilla and Alessandro Parolari and Marina Camera and Susanna Colli and Sonia Eligini and Chiara Centenaro and Achille Anselmo and Francesco Alamanni and Elena Tremoli",
year = "2010",
month = "3",
doi = "10.1160/TH09-07-0470",
language = "English",
volume = "103",
pages = "516--524",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "3",

}

TY - JOUR

T1 - Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery

AU - Brambilla, Marta

AU - Parolari, Alessandro

AU - Camera, Marina

AU - Colli, Susanna

AU - Eligini, Sonia

AU - Centenaro, Chiara

AU - Anselmo, Achille

AU - Alamanni, Francesco

AU - Tremoli, Elena

PY - 2010/3

Y1 - 2010/3

N2 - Early post-operative aspirin improves survival in patients undergoing coronary artery bypass graft (CABG). However, most patients do not benefit of aspirin after CABG, still remaining at risk of thrombotic events due to insufficient platelet inhibition, specifically via the thromboxane (TX) pathway. We evaluated the effect of two aspirin doses (100 or 325 mg daily, enteric coated formulations) on platelet function and TX biosynthesis in patients after CABG and assessed whether the incidence of residual platelet reactivity could be reduced by the higher dose. Fifty-six patients undergoing CABG were randomly assigned to 100 or 325 mg aspirin daily for five days in a prospective single-centre study. Treatment effect was assessed by measuring either platelet function (light-transmission aggregometry and point-of-care PFA-100® ) or TX biosynthesis in collagen-stimulated platelets, serum, urine, and in lipopolysaccharide (LPS)-cultured whole blood (WB). An insufficient TX inhibition was observed with 100 mg aspirin but not with the higher dose. The different effect of the two doses was, however, highlighted by either TX (platelet- or serum-derived) or by PFA-100® but not by the other assays. In conclusion, early after CABG, the incidence of residual platelet activity was lower in patients who received 325 mg aspirin. Moreover, evidence was provided that different methods yield different results in the detection of aspirin resistance, rendering them not interchangeable.

AB - Early post-operative aspirin improves survival in patients undergoing coronary artery bypass graft (CABG). However, most patients do not benefit of aspirin after CABG, still remaining at risk of thrombotic events due to insufficient platelet inhibition, specifically via the thromboxane (TX) pathway. We evaluated the effect of two aspirin doses (100 or 325 mg daily, enteric coated formulations) on platelet function and TX biosynthesis in patients after CABG and assessed whether the incidence of residual platelet reactivity could be reduced by the higher dose. Fifty-six patients undergoing CABG were randomly assigned to 100 or 325 mg aspirin daily for five days in a prospective single-centre study. Treatment effect was assessed by measuring either platelet function (light-transmission aggregometry and point-of-care PFA-100® ) or TX biosynthesis in collagen-stimulated platelets, serum, urine, and in lipopolysaccharide (LPS)-cultured whole blood (WB). An insufficient TX inhibition was observed with 100 mg aspirin but not with the higher dose. The different effect of the two doses was, however, highlighted by either TX (platelet- or serum-derived) or by PFA-100® but not by the other assays. In conclusion, early after CABG, the incidence of residual platelet activity was lower in patients who received 325 mg aspirin. Moreover, evidence was provided that different methods yield different results in the detection of aspirin resistance, rendering them not interchangeable.

KW - Aspirin

KW - Coronary surgery

KW - Platelet aggregation

KW - Platelet pharmacology

KW - Thromboxane

UR - http://www.scopus.com/inward/record.url?scp=77749289650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749289650&partnerID=8YFLogxK

U2 - 10.1160/TH09-07-0470

DO - 10.1160/TH09-07-0470

M3 - Article

C2 - 20076848

AN - SCOPUS:77749289650

VL - 103

SP - 516

EP - 524

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 3

ER -